US FDA Accelerated Approvals Could Expire Under New Legislation, But Big Loophole Included
Executive Summary
The bill, some version of which is undoubtedly destined for the FDA user fee package, also would codify existing labeling guidance for products cleared through the pathway.
You may also be interested in...
US FDA Wants To Help Sponsors Generate Evidence CMS Needs, But Won't Be An Intermediary
FDA-CMS communications are expected to evolve as both agencies look to improve their relationship.
Accelerated Approvals Need Earlier Planning On Surrogate Endpoints, Postmarketing Trials – FDA’s Marks
Current accelerated approval provisions are the ‘sweet spot’ for balancing access and efficacy, but more attention needs to be paid by sponsors and the agency to working out regulatory pain points earlier in the development process, CBER director tells gene/cell therapy conference.
Elizabeth Jungman: Interpreter Of The FDA’s Policy Crystal Ball
The Center for Drug Evaluation and Research’s policy guru must think about the future, along with the present, in her position as director of the Office of Regulatory Policy.